Abstract | OBJECTIVE: METHODS: PubMed® and EMBASE databases were searched to identify studies that examined the effect of the NAT1*10 allele on the risk of bladder cancer. RESULTS: Eleven case-control studies, which included 3311 bladder cancer cases and 3906 control subjects, met the inclusion criteria. The pooled analyses based on all studies showed that there was no significant difference in the NAT1*10 allele between bladder cancer cases and controls (odds ratios [OR] 0.96; 95% confidence interval [CI] 0.81, 1.10). When stratifying for race, the results were similar among Caucasians (OR 0.96; 95% CI 0.81, 1.12) and Asians (OR 0.87; 95% CI 0.48, 1.56). No statistical association was found between the NAT1*10 allele and bladder cancer risk upon stratification for smoking status and study design. CONCLUSIONS: This meta-analysis suggests that there was no association between the NAT1*10 allele and bladder cancer risk. Further research should focus on other potentially functional genetic polymorphisms.
|
Authors | Ke Wu, Xianding Wang, Zhiyuan Xie, Zhihong Liu, Yiping Lu |
Journal | The Journal of international medical research
(J Int Med Res)
Vol. 41
Issue 1
Pg. 31-7
(Feb 2013)
ISSN: 1473-2300 [Electronic] England |
PMID | 23569127
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- Isoenzymes
- Arylamine N-Acetyltransferase
- N-acetyltransferase 1
|
Topics |
- Alleles
- Arylamine N-Acetyltransferase
(genetics)
- Genetic Predisposition to Disease
- Humans
- Isoenzymes
(genetics)
- Odds Ratio
- Polymorphism, Genetic
- Urinary Bladder Neoplasms
(enzymology, epidemiology, genetics)
|